Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3396-3403

  Howell, A ^a   Robertson, J F R ^a   Albano, J Quaresma ^a   Aschermannova, A ^a   Mauriac, L ^a   Kleeberg, U R ^a   Vergote, I ^a   Erikstein, B ^a   Webster, A ^a   Morris, C ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; FULVESTRANT; LETROZOLE; TAMOXIFEN CITRATE;

ADULT; AGED; ARTICLE; ASTHENIA; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PAIN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM METASTASIS; NITRILES; POSTMENOPAUSE; QUALITY OF LIFE; SURVIVAL RATE; TRIAZOLES;

EID: 0037102121     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.10.057     Document Type: Article

References (20)

1. Tamoxifen: The herald of a new era of preventive therapeutics
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
3. A potent specific pure antioestrogen with clinical potential
4. The antitumor effects of single dose, long acting Faslodex™ (ICI 182780) compared with tamoxifen in post-menopausal primary breast cancer patients treated before surgery
5. Comparison of the effects of a pure steroidal antioestrogen with those of tamoxifen in a model of human breast cancer
6. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
7. Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer
8. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial
9. A study of the use of the probability of being in response function as a summary of tumor response data
10. The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure
11. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument
12. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women: Combined analysis from two identically designed multicenter trials
13. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
14. Anastrozole vs tamoxifen in hormone-dependent advanced breast cancer: A phase II randomized trial
15. New endocrine therapies for breast cancer
16. Effects of high dose raloxifene in selected patients with advanced breast carcinoma
17. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment
18. Multicenter phase II efficacy trial of toremifene in tamoxifen refractory patients with advanced breast cancer
19. Phase II evaluations of LY 156758 in metastatic breast cancer
20. Preliminary results of a randomized double-blind phase II study of the selective estrogen receptor modulator (SERM) arzoxifene (AZ) in patients (Pts) with locally advanced or metastatic breast cancer (MBC)